Paclitaxel and carboplatin after disease progression on immune checkpoint inhibitor for patients with metastatic urothelial carcinoma.

Jang A, Muniz M, Spychalla M, Burns T, Singh A, Heath EI, Costello BA, Orme JJ, Quevedo JF, Childs DS, Pagliaro LC

Open source

DOI: 10.37349/etat.2026.1002387
Published: 2026
Container: Exploration of targeted anti-tumor therapy
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.37349/etat.2026.1002387,
  title = {Paclitaxel and carboplatin after disease progression on immune checkpoint inhibitor for patients with metastatic urothelial carcinoma.},
  author = {Jang A and Muniz M and Spychalla M and Burns T and Singh A and Heath EI and Costello BA and Orme JJ and Quevedo JF and Childs DS and Pagliaro LC},
  year = {2026},
  journal = {Exploration of targeted anti-tumor therapy},
  doi = {10.37349/etat.2026.1002387},
  url = {https://doi.org/10.37349/etat.2026.1002387}
}

RIS

TY  - JOUR
TI  - Paclitaxel and carboplatin after disease progression on immune checkpoint inhibitor for patients with metastatic urothelial carcinoma.
AU  - Jang A
AU  - Muniz M
AU  - Spychalla M
AU  - Burns T
AU  - Singh A
AU  - Heath EI
AU  - Costello BA
AU  - Orme JJ
AU  - Quevedo JF
AU  - Childs DS
AU  - Pagliaro LC
PY  - 2026
JO  - Exploration of targeted anti-tumor therapy
DO  - 10.37349/etat.2026.1002387
UR  - https://doi.org/10.37349/etat.2026.1002387
ER  -

APA

A, J., M, M., M, S., T, B., A, S., EI, H., BA, C., JJ, O., JF, Q., DS, C., & LC, P. (2026). Paclitaxel and carboplatin after disease progression on immune checkpoint inhibitor for patients with metastatic urothelial carcinoma.. Exploration of targeted anti-tumor therapy. https://doi.org/10.37349/etat.2026.1002387

Source records

pubmed · retrieved 2026-09-25T14:49:56.843Z
europe-pmc · retrieved 2026-09-25T14:49:56.855Z
doaj · retrieved 2026-09-25T14:49:56.848Z